PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension

被引:9
作者
Jiang, Yanli [1 ]
Li, Qiang [1 ]
Jia, Mengxiao [1 ]
Yan, Zhencheng [1 ]
机构
[1] Army Med Univ, Dept Hypertens & Endocrinol, Ctr Hypertens & Metab Dis, Daping Hosp,Chongqing Inst Hypertens, Chongqing 400042, Peoples R China
基金
中国国家自然科学基金;
关键词
ACTIVATED-RECEPTOR-DELTA; ENDOTHELIAL DYSFUNCTION; CELL PROLIFERATION; INSULIN-RESISTANCE; SKELETAL-MUSCLE; BETA/DELTA; AGONIST; DISEASE; MODULATION; EXPRESSION;
D O I
10.1155/2019/7809216
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High blood pressure and its associated cardiovascular diseases have been major risks for public health. Multiple metabolic risk factors can cause the vascular dysfunction and vascular lesion, and the hypertension due to metabolic disturbances was defined as metabolic hypertension. The members of a subfamily of the nuclear receptors, peroxisome proliferator-activated receptors (PPARs), were found to be key regulators of metabolism and vascular function. We provide up-to-date knowledge on the role of subtype PPAR delta in the regulation of metabolism and vascular function and the effect of its intervention on the metabolic hypertension management. We hope to give some insights into the development of more effective treatments of metabolic hypertension and its main complications.
引用
收藏
页数:7
相关论文
共 62 条
  • [1] Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-β/δ gene
    Adamkiewicz, Juergen
    Kaddatz, Kerstin
    Rieck, Markus
    Wilke, Bernhard
    Mueller-Bruesselbach, Sabine
    Mueller, Rolf
    [J]. PROTEOMICS, 2007, 7 (08) : 1208 - 1216
  • [2] PPARδ: a link between sodium and glucose homeostasis
    Susan J. Allison
    [J]. Nature Reviews Nephrology, 2016, 12 (6) : 313 - 313
  • [3] Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer
    Barak, Y
    Liao, D
    He, WM
    Ong, ES
    Nelson, MC
    Olefsky, JM
    Boland, R
    Evans, RM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (01) : 303 - 308
  • [4] Benetti Elisa, 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P273
  • [5] PPARs and angiogenesis
    Bishop-Bailey, David
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 1601 - 1605
  • [6] Proteomic analysis of vascular endothelial growth factor-induced endothelial cell differentiation reveals a role for chloride intracellular channel 4 (CLIC4) in tubular morphogenesis
    Bohman, S
    Matsumoto, T
    Suh, K
    Dimberg, A
    Jakobsson, L
    Yuspa, S
    Welsh, LC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (51) : 42397 - 42404
  • [7] Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor γ and δ in Vascular Diseases
    Cheang, Wai San
    Fang, Xi
    Tian, Xiao Yu
    [J]. CIRCULATION JOURNAL, 2013, 77 (11) : 2664 - 2671
  • [8] Paeonol protects against endoplasmic reticulum stress-induced endothelial dysfunction via AMPK/PPARδ signaling pathway
    Choy, Ker-Woon
    Mustafa, Mohd Rais
    Lau, Yeh Siang
    Liu, Jian
    Murugan, Dharmani
    Lau, Chi Wai
    Wang, Li
    Zhao, Lei
    Huang, Yu
    [J]. BIOCHEMICAL PHARMACOLOGY, 2016, 116 : 51 - 62
  • [9] Rationally designed PPARδ-specific agonists and their therapeutic potential for metabolic syndrome
    Cox, Rebecca L.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (13) : 3284 - 3285
  • [10] The wrong white crystals: not salt but sugar as aetiological in hypertension and cardiometabolic disease
    DiNicolantonio, James J.
    Lucan, Sean C.
    [J]. OPEN HEART, 2014, 1 (01):